Subtopic Deep Dive

Precision Medicine for BRCA Carriers
Research Guide

What is Precision Medicine for BRCA Carriers?

Precision medicine for BRCA carriers applies targeted therapies like PARP inhibitors to exploit homologous recombination deficiency in BRCA-mutated cancers.

This subtopic centers on PARP inhibitors and biomarkers for BRCA1/2-mutated breast, ovarian, and other cancers. Clinical guidelines from NCCN recommend genetic testing and risk management (Daly et al., 2021, 1069 citations; Daly et al., 2020, 485 citations). Over 10 papers in the corpus address risks, therapies, and genomic scars, with Slade (2020) reviewing PARP inhibitors (635 citations).

Curated Papers

Key Challenges

Why It Matters

PARP inhibitors improve survival in BRCA-mutated ovarian cancer by synthetic lethality, guiding patient selection via HRD signatures (Slade, 2020; Marquard et al., 2015). NCCN guidelines enable risk-based screening and preventive surgeries for carriers, reducing breast and ovarian cancer incidence (Daly et al., 2021; Kuchenbaecker et al., 2017). These approaches personalize treatment, avoiding overtreatment in non-BRCA cases and informing prostate cancer testing (Nicolosi et al., 2019).

Key Research Challenges

PARP Inhibitor Resistance

Tumors develop resistance through reversion mutations restoring BRCA function. Clinical trials show variable efficacy needing better biomarkers (Slade, 2020). Strategies combine PARP with other agents to overcome this (Marquard et al., 2015).

Biomarker Validation

HRD genomic scar signatures predict response but require pan-cancer standardization. Assays like those in Marquard et al. (2015) identify indications beyond BRCA status. Validation across tumor types remains inconsistent (Daly et al., 2021).

Carrier Risk Stratification

Family history and mutation location modulate cancer risks beyond germline status. Prospective data refine models but guidelines lag (Kuchenbaecker et al., 2017). Integrating polygenic risks poses implementation hurdles (Daly et al., 2020).

Essential Papers

Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes et al. · 2017 · JAMA · 2.7K citations

These findings provide estimates of cancer risk based on BRCA1 and BRCA2 mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mut...

Awareness and current knowledge of breast cancer

Muhammad Akram, Mehwish Iqbal, Muhammad Daniyal et al. · 2017 · Biological Research · 1.3K citations

Breast cancer remains a worldwide public health dilemma and is currently the most common tumour in the globe. Awareness of breast cancer, public attentiveness, and advancement in breast imaging has...

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Mary B. Daly, Tuya Pal, Michael P. Berry et al. · 2021 · Journal of the National Comprehensive Cancer Network · 1.1K citations

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased ri...

A brief history of human disease genetics

Melina Claussnitzer, Judy H. Cho, Rory Collins et al. · 2020 · Nature · 700 citations

PARP and PARG inhibitors in cancer treatment

Dea Slade · 2020 · Genes & Development · 635 citations

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying genomic instability through radiotherapy and chemotherapy has been a powerful but nonselective means of kil...

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

Mary B. Daly, Robert Pilarski, Matthew B. Yurgelun et al. · 2020 · Journal of the National Comprehensive Cancer Network · 485 citations

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk m...

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

Piper Nicolosi, Elisa M. Ledet, Shan Yang et al. · 2019 · JAMA Oncology · 351 citations

Current NCCN guidelines and Gleason scores cannot reliably stratify patients with prostate cancer for the presence or absence of pathogenic germline variants. Most positive genetic test results ide...

Reading Guide

Foundational Papers

Start with Kuchenbaecker et al. (2017) for BRCA risk estimates in carriers, then Daly et al. (2020) for NCCN testing guidelines to ground clinical decision-making.

Recent Advances

Study Slade (2020) on PARP inhibitors, Daly et al. (2021) for updated NCCN recommendations, and Marquard et al. (2015) for HRD biomarker applications.

Core Methods

Core techniques: PARP inhibition (Slade 2020), genomic scar profiling (Marquard 2015), germline variant assessment via NCCN protocols (Daly et al., 2021).

How PapersFlow Helps You Research Precision Medicine for BRCA Carriers

Discover & Search

Research Agent uses searchPapers('PARP inhibitors BRCA precision medicine') to retrieve Slade (2020) and Daly et al. (2021), then citationGraph to map 635+ citations linking PARP to HRD therapies, and findSimilarPapers on Marquard et al. (2015) for pan-cancer HRD scars.

Analyze & Verify

Analysis Agent applies readPaperContent on Slade (2020) to extract resistance mechanisms, verifyResponse with CoVe against NCCN guidelines (Daly et al., 2021), and runPythonAnalysis to plot HRD scar distributions from Marquard et al. (2015) data using pandas, earning GRADE A for evidence strength in synthetic lethality claims.

Synthesize & Write

Synthesis Agent detects gaps in resistance biomarkers post-Slade (2020), flags contradictions between risk models (Kuchenbaecker et al., 2017 vs. Daly et al., 2021), and Writing Agent uses latexEditText with latexSyncCitations to draft therapy protocols, latexCompile for PDF, and exportMermaid for HRD pathway diagrams.

Use Cases

"Analyze HRD scar data from BRCA papers to predict PARP response rates"

Research Agent → searchPapers('HRD BRCA') → Analysis Agent → readPaperContent(Marquard 2015) → runPythonAnalysis(pandas plot of scar signatures vs. drug response) → statistical verification output with p-values and matplotlib figures.

"Draft NCCN-compliant protocol for BRCA ovarian cancer treatment"

Research Agent → exaSearch('NCCN BRCA guidelines') → Synthesis Agent → gap detection(Daly 2021) → Writing Agent → latexEditText(protocol draft) → latexSyncCitations(10 papers) → latexCompile(PDF review-ready protocol).

"Find GitHub repos implementing BRCA risk calculators from papers"

Research Agent → searchPapers('BRCA risk model code') → Code Discovery → paperExtractUrls(Kuchenbaecker 2017) → paperFindGithubRepo → githubRepoInspect(analyze risk prediction scripts) → exportCsv(model benchmarks).

Automated Workflows

Deep Research workflow scans 50+ BRCA papers via searchPapers and citationGraph, producing structured reports on PARP efficacy with GRADE scores from Analysis Agent. DeepScan applies 7-step verification on Slade (2020) claims using CoVe and runPythonAnalysis for mutation frequency stats. Theorizer generates hypotheses on HRD biomarkers by synthesizing Marquard et al. (2015) scars with NCCN guidelines (Daly et al., 2021).

Try Doxa for Precision Medicine for BRCA Carriers Research

Frequently Asked Questions

What defines precision medicine for BRCA carriers?

It targets homologous recombination deficiency with PARP inhibitors in BRCA1/2-mutated cancers, as reviewed by Slade (2020).

What are main methods in this subtopic?

PARP inhibition exploits synthetic lethality; HRD scar analysis predicts response (Marquard et al., 2015); NCCN recommends germline testing and risk management (Daly et al., 2021).

What are key papers?

Foundational: Kuchenbaecker et al. (2017, 2687 citations) on risks; Recent: Slade (2020, 635 citations) on PARP inhibitors; Guidelines: Daly et al. (2021, 1069 citations).

What are open problems?

Overcoming PARP resistance, standardizing HRD biomarkers across cancers, and refining risk models with family history (Slade 2020; Marquard 2015; Kuchenbaecker 2017).